CIP2A is a predictor of poor prognosis in colon cancer

Journal of Gastrointestinal Surgery

Volumn 16, Issue 5, 2012, Pages 1037-1047

  Teng, Hao Wei ^a,b   Yang, Shung Haur ^a,b   Lin, Jen Kou ^a,b   Chen, Wei Shone ^a,b   Lin, Tzu Chen ^a,b   Jiang, Jeng Kai ^a,b   Yen, Chueh Chuan ^a,b   Li, Anna Fen Yau ^a,b   Chen, Paul Chih Hsueh ^a,b   Lan, Yuan Tzu ^a,b   Lin, Chun Chi ^a,b   Hsu, Yen Ning ^d,e   Wang, Hsei Wei ^b   Chen, Kuen Feng ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chemotherapy; Cip2a; Colon cancer; Mapk pathway; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOANTIGEN; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; RNA; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CELL PROLIFERATION; COLON TUMOR; COLORECTAL TUMOR; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROTEIN MICROARRAY; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SURVIVAL; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AUTOANTIGENS; BIOPSY, NEEDLE; BLOTTING, WESTERN; CELL PROLIFERATION; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA, NEOPLASM; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84865340654     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-012-1828-3     Document Type: Article

References (24)

1. Naishadham D, Lansdorp-Vogelaar I, Siegel R, Cokkinides V, Jemal A. State disparities in colorectal cancer mortality patterns in the United States. Cancer Epidemiol Biomarkers Prev 2011; 20: 1296-1302
2. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345
3. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019
4. Novak R, Zeng Y, Shuga J, Venugopalan G, Fletcher DA, Smith MT, Mathies RA. Single-cell multiplex gene detection and sequencing with microfluidically generated agarose emulsions. Angew Chem Int Ed Engl 2011; 50: 390-395
5. Hoving JL, de Vet HC, Twisk JW, Deville WL, van der Windt D, Koes BW, Bouter LM. Prognostic factors for neck pain in general practice. Pain 2004; 110: 639-645
6. Montagnani F, Chiriatti A, Turrisi G, Francini G, Fiorentini G. A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Colorectal Dis 2011; 13: 846-852
7. Junttila MR, Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell Cycle 2008; 7: 592-596
8. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grenman R, Kast J, Kallunki T, Sears R, Kahari VM, Westermarck J. CIP2A inhibits PP2A in human malignancies. Cell 2007; 130: 51-62
9. Vaarala MH, Vaisanen MR, Ristimaki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010; 29: 136
10. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thezenas S, Westermarck J. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009; 15: 5092-5100
11. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, Xu D. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 2008; 14: 3722-3728
12. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, Wang EH. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2010; 18: 857-865.
13. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010; 29: 6257-6266.
14. Coenen EA, Zwaan CM, Meyer C, Marschalek R, Pieters R, van der Veken LT, Beverloo HB, van den Heuvel-Eibrink MM. KIAA1524: a novel MLL translocation partner in acute myeloid leukemia. Leuk Res 2010; 35: 133-135.
15. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimaki A. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009; 101: 793-805
16. Bockelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Butzow R, Ristimaki A. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 2011; 105: 989- 995
17. Yang MH, Chiang WC, Chou TY, Chang SY, Chen PM, Teng SC, Wu KJ. Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation. Clin Cancer Res 2006; 12: 507-515
18. Choi YA, Park JS, Park MY, Oh KS, Lee MS, Lim JS, Kim KI, Kim KY, Kwon J, Yoon do Y, Moon EY, Yang Y. Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett 2011; 585: 755-760
19. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005; 6: 322-327
20. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249-279
21. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308-1324
22. Zhao D, Liu Z, Ding J, Li W, Sun Y, Yu H, Zhou Y, Zeng J, Chen C, Jia J. Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK/ERK pathways. J Med Microbiol 2010; 59: 259-265
23. Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 2009; 1795: 1-15
24. Dhillon AS, Meikle S, Yazici Z, Eulitz M, Kolch W. Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J 2002; 21: 64-71